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A B S T R A C T
Infections with parasitic nematodes are among the most signiﬁcant of the neglected tropical diseases aﬀecting
about a billion people living mainly in tropical regions with low economic activity.
The most eﬀective current strategy to control nematode infections involves large scale treatment programs
with anthelmintic drugs. This strategy is at risk from the emergence of drug resistant parasites. Parasitic ne-
matodes also aﬀect livestock, which are treated with the same limited group of anthelmintic drugs. Livestock
parasites resistant to single drugs, and even multi-drug resistant parasites, are appearing in many areas. There is
therefore a pressing need for new anthelmintic drugs.
Here we use the nematode Caenorhabditis elegans as a model for parasitic nematodes and demonstrate that
sinefungin, a competitive inhibitor of methyltransferases, causes a delay in development and reduced fecundity,
and inhibits spliced leader trans-splicing. Spliced leader trans-splicing is an essential step in gene expression that
does not occur in the hosts of parasitic nematodes, and is therefore a potential target for new anthelmintic drugs.
We have exploited the ability of sinefungin to inhibit spliced leader trans-splicing to adapt a green ﬂuorescent
protein based reporter gene assay that monitors spliced leader trans-splicing for high-throughput screening for
new anthelmintic compounds. We have established a protocol for robust high-throughput screening, combining
mechanical dispensing of living C. elegans into 384- or 1536- well plates with addition of compounds using an
acoustic liquid dispenser, and the detection of the inhibition of SL trans-splicing using a microplate reader. We
have tested this protocol in a ﬁrst pilot screen and envisage that this assay will be a valuable tool in the search for
new anthelmintic drugs.
1. Introduction
Parasitic nematode infections are the cause of several of the major
neglected tropical diseases identiﬁed by the World Health Organization
that cause long-term disability and can lead to disﬁgurement (Hotez,
2013). Hookworm infections, ascariasis and trichuriasis are the most
prevalent neglected tropical diseases, aﬀecting predominantly “the
bottom billion” of the world population living in extreme poverty in
regions where these parasites are endemic (Collier, 2008; Hotez, 2013).
Frequently, individuals suﬀer from two or all three of these conditions.
There is good evidence that they aﬀect physical and mental
development, causing stunted growth and deﬁcits in memory, in-
telligence and cognition (Crompton, 2000; Bethony et al., 2006).
Parasitic nematodes also impact on livestock production, and infect
equids and companion animals, with annual treatment costs (not in-
cluding the loss of production) in the tens of billion dollars worldwide
(Roeber et al., 2013).
Currently, the most eﬀective strategy to control nematode infections
is the use of anthelmintic drugs. The World Health Organization ad-
vocates periodic, community-wide treatment with anthelmintic drugs
focusing predominantly on school-age children, which are at particular
risk of infection (WHO Resolution 54.19, 2001). This strategy, with
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treatments using compounds belonging to the benzimidazole class of
anthelmintics, has led to clear health and ﬁtness beneﬁts with im-
provements in physical development and mental abilities (Hotez,
2013).
However, this approach is jeopardised by emerging resistance
against anthelmintic drugs. In livestock parasites, resistance against the
three long-used major classes of anthelmintic drugs, benzimidazoles,
imidothiazoles/tetrahydropyrimidines and macrocyclic lactones, is
widespread, and there are even recent reports of resistance against the
newest drug, the amino-acetonitrile derivative monepantel (Kaplan and
Vidyashankar, 2012; Mederos et al., 2014). Treatment regimes of
human populations need to be carefully monitored and managed to
minimise the risk of the emergence of drug resistant human parasites
(Vercruysse et al., 2011). A recent report of a reduced eﬃcacy of
treatment with albendazole raises the suspicion of the emergence of
drug resistant Ascaris lumbricoides (Krücken et al., 2017). This high-
lights that there is an urgent need for the identiﬁcation of anthelmintics
with novel mechanisms of action.
Here we describe the adaptation of a GFP-based assay that detects
the inhibition of spliced leader 1 trans-splicing (SL1 trans-splicing) in
living C. elegans for high-throughput screening (Philippe et al., 2017).
Spliced leader trans-splicing is conserved across the nematode phylum
and occurs in cestodes and trematodes, but does not occur in verte-
brates or plants (Rajkovic et al., 1990; Brehm et al. 2000, 2002; Lasda
and Blumenthal, 2011; Pettitt et al., 2014). SL1 trans-splicing involves
the transfer of the short SL1 RNA fragment from a non-polyadenylated
RNA, called the spliced leader RNA (SL1 RNA), onto the 5’ end of a pre-
mRNA molecule (Krause and Hirsh, 1987) (Fig. 1A). Spliced leader
trans-splicing also requires the U2 snRNP and the U4/U6.U5 tri-snRNP
involved in intron removal by cis-splicing (Hannon et al., 1991;
Maroney et al., 1996).
Importantly, spliced leader trans-splicing is an essential function
that requires the SL RNA and associated proteins. Animals are most
sensitive to the inhibition of SL1 trans-splicing during early develop-
ment when extensive gene expression is required for cell division and
diﬀerentiation: both loss of SL1 RNA genes and RNAi knockdown of the
essential spliced leader trans-splicing factor SNA-2 lead to embryonic
lethality (Ferguson et al., 1996; MacMorris et al., 2007).
Our GFP-based assay produces functional GFP protein in the intes-
tine of adult animals when SL1 trans-splicing is inhibited (Philippe
et al., 2017) (Fig. 1B). This allows the detection of inhibition of SL1
trans-splicing independent of eﬀects on early development. Based on
our investigation of factors involved in SL1 trans-splicing, reporter gene
activation occurs in response to the depletion of the function of non-
essential factors such as SNA-1, whose loss causes cold-sensitive defects
in viability, as well as clearly essential factors such as SNA-2, indicating
that the assay can be used for the detection of compounds that inhibit
SL1 trans-splicing to such a degree that they cause lethality (Philippe
et al., 2017).
The reporter system was designed to detect factors whose inhibition
preferentially interferes with SL1 trans-splicing. The GFP reporter gene
contains three introns; any compound with a severe eﬀect on cis-spli-
cing should not lead to reporter gene activation as intron inclusion
generates non-functional transcripts containing premature termination
codons. However, we envisage that as part of the characterisation of
any inhibitors of SL1 trans-splicing additional tests will need to be done
to speciﬁcally rule out any eﬀects on cis-splicing of host transcripts.
Here, we use this assay to demonstrate that sinefungin inhibits SL1
trans-splicing. Sinefungin is a naturally occurring nucleoside with si-
milarity to S-adenosyl-1-methionine (Barbés et al., 1990), and acts as an
inhibitor of methyltransferases involved in the methylation of nucleic
acids and proteins (Vedel et al., 1978; Borchardt et al., 1979).
We have exploited the ability of sinefungin to inhibit SL1 trans-
splicing to adapt our GFP-based assay for liquid-based, semi-automated
identiﬁcation of novel anthelmintic compounds via high-throughput
screening (HTS). The HTS assay combines automated liquid dispensers
for the addition of nematodes and compounds into 384- or 1536-well
plates, with the subsequent detection of GFP production following SL
trans-splicing inhibition using a microplate reader. The assay was de-
veloped to provide suitable robustness and reproducibility for HTS, as
deﬁned by Z′-factor values of ≥0.5 (Zhang et al., 1999). We have
executed a pilot screen, demonstrating the feasibility of HTS, and test
the eﬀects of some key modiﬁcation on the robustness of the assay.
2. Materials and methods
2.1. Sinefungin and isoginkgetin
Sinefungin was purchased from Enzo Life Sciences (ALX-380-070-
M005). A 40mM sinefungin stock solution was prepared in DMSO
(Sigma-Aldrich, 276855). Lower concentrations were prepared by serial
dilution in DMSO and stored at−20 °C until required. Isoginkgetin was
purchased from Merck (416154-10) and dissolved at 40mM in DMSO.
Working stocks of 1mM, 5mM and 20mM were prepared by dilution in
DMSO.
2.2. C. elegans strains
Strains used were PE796 [fem-1(hc17) IV; feIs14 [Pvit-
2::outron::gfpM1A Pmyo-3::mCherry] V] and PE797 [fem-1(hc17) IV; feIs14
[Pvit-2::outron::gfpM1A Pmyo-3::mCherry] V; bus-8(e2698) X]. The C. elegans
strains were maintained on NGM agar plates with a lawn of Escherichia
Fig. 1. A. SL1 trans-splicing mechanism. SL1 spliced leader trans-splicing is
the addition of a specialised exon known as the spliced leader 1 (SL1) to the 5′
ends of pre-mRNA transcripts at the SL1 splice acceptor site, resulting in the
removal of the 5′ untranslated region referred to as the “outron”. The spliced
leader SL1 is donated by a separate RNA, the SL1 RNA. B. A GFP based in vivo
assay that monitors SL1 trans-splicing. Schematic representation of the gfp
reporter gene with the outron sequence and the SL1 splice acceptor site 3′ of the
ATG initiation codon (schematic adapted from (Philippe et al., 2017)). During
SL1 trans-splicing, the outron sequence is removed from gfpmRNA and replaced
by SL1, resulting in the removal of the initiation codon and thus preventing
synthesis of functional GFP. Inhibition of SL1 trans-splicing results in GFP ex-
pression, because the start codon is retained in the gfp reporter mRNA. Presence
and absence of SL1 trans-splicing are indicated with GO and STOP signs, re-
spectively.
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coli strain OP50 (Brenner, 1974; Stiernagle, 2006) in a temperature-
controlled incubator at 20°C.
2.3. Development and egg viability assays
Approximately 50 eggs or 20 synchronous L1 larvae were applied
onto 3 cm NGM agar plates with or without 1% DMSO, or with 1%
DMSO and 400 μM sinefungin, and seeded with an OP50 lawn
(Stiernagle, 2006). Development was monitored at 12–15 h intervals for
up to 80 h at 25°C. To test egg viability, single worms were added to ten
3 cm NGM agar plates with or without 1% DMSO, or with 1% DMSO
and 400 μM sinefungin, and incubated at 25°C. Adults were moved to
fresh plates every 12 h (plates with/without DMSO) or 16 h (plates with
sinefungin/DMSO), and eggs were left to hatch at 25°C. The numbers of
eggs and hatched eggs were recorded.
2.4. Preparation of bacteria for feeding
Concentrated pellets of OP50 bacteria were prepared as described
and stored at −20°C (Stiernagle, 2006).
2.5. Liquid culture of C. elegans
Age-synchronous C. elegans cultures were produced by treatment of
gravid animals from 4 to 5 10 cm petri plates with hypochlorite solution
(Stiernagle, 2006). Eggs were resuspended in 120ml M9 buﬀer sup-
plemented with 1% LB broth (Leung et al., 2011), transferred into a 1 L
spinner ﬂask (Corning 4500-1L) and grown under constant stirring at
200 rpm at 25°C. Alternatively, the eggs were resuspended in 25 or
30ml M9 buﬀer supplemented with 1% LB broth and transferred into
250ml or 500ml sterile ﬂask, and grown at 25°C in a temperature-
controlled orbital shaking incubator at 160 rpm.
After overnight incubation, L1 larvae were collected by cen-
trifugation and resuspended at a density of 2000–2500 animals/ml in
120ml S-complete medium supplemented with 16–18mg/ml OP50 E.
coli (Stiernagle, 2006). Animals were grown to adults in a 1 L spinner
ﬂask stirred at 200 rpm at 25°C. Alternatively, 25ml or 30ml cultures
were grown in 250ml or 500ml glass ﬂasks at 25°C in a shaking in-
cubator. Animals were allowed to settle under gravity at room tem-
perature for 10min (Leung et al., 2011). Then the animals were washed
once in S-complete medium and then resuspended in S-complete
medium supplemented with 4–6mg/ml OP50 E. coli at a density of
1000–1250 animals/ml. Alternatively, animals were washed twice in S-
complete medium and then resuspended at a density of 1000–1250
animals/ml.
2.6. High-throughput screening
For dispensing the animals into 384- or 1536-well plates, 40ml C.
elegans suspension at a density of 1000–1250 animals/ml prepared as
described under 2.5 above was transferred into a sterile 50 ml glass
bottle with a magnetic stirrer bar and stirred at 80 rpm at room tem-
perature. Animals were dispensed into 384- or 1536-well plates using a
Multidrop™ Combi Reagent Dispenser (Thermo Scientiﬁc 84030) with a
standard dispensing cassette (Thermo Scientiﬁc 24072670) using de-
fault settings. Where indicated, a Matrix WellMate™ (Thermo Scientiﬁc
201-10001) with a 8-channel standard bore tubing cartridge (Thermo
Scientiﬁc 201-30001) was used instead. Equipment was sterilised and
rinsed with 70% ethanol and then sterile water before use. The number
of animals dispensed per well was tested using clear bottom 384-well
plates (Greiner Bio-One 781097) and if necessary the density of animals
was adjusted to dispense 20-25 animals in 20 μl into 384-well plates or
5–10 animals in 10 μl into 1536-well plates. For screening, animals
were dispensed into black opaque 384-well plates (Greiner Bio-One,
784076) or 1536-well plates (Greiner Bio-one, 783076).
Sinefungin dissolved in DMSO was added to ﬁnal concentrations of
400 μM sinefungin/2% DMSO, and 800 μM sinefungin/2% DMSO using
an acoustic liquid dispenser (ECHO 550 from Labcyte, Inc). Treatment
with 2% DMSO only was done as a control. The plates were kept in
closed plastic containers humidiﬁed by including tissue soaked with
distilled water and incubated at 25°C. GFP ﬂuorescence was measured
using a PHERAstar FS microplate reader (BMG Labtech, Inc) with ex-
citation/emission wavelengths of 485/520 nm in top reading mode.
Samples were normally measured using the orbital averaging mode
with 25 ﬂashes per read.
Assay robustness and reproducibility were tested by calculating the
Z′-factor (Zhang et al., 1999) and the signal to background (S/B) ratio
using equations (1) and (2) shown below, using the mean (μ) and
standard deviation (σ) of the GFP signal from sinefungin-treated (P) and
DMSO only treated animals (N). The standard deviation of S/B was
approximated using formula (3).
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2.7. Drug library screening
A library of 5195 structurally diverse drug-like compounds was
obtained from the BioAscent Compound Cloud (www.bioascent.com/
compoundcloud/, BioAscent, Biocity Scotland, Newhouse, Scotland). In
addition, 727 compounds from the NIH Clinical Collection and 853
compounds custom selected from the SelleckChem screening libraries
collection were tested. Screening was done in 384-well plates. On each
plate, PE796 animals were also treated with 800 μM sinefungin/2%
DMSO or with 2% DMSO. Animals were exposed to compounds at a
concentration of 50 μM in the presence or absence of OP50 bacteria,
and ﬂuorescence was captured after 4 h using a PHERAstar FS micro-
plate reader as described above. Z′-factor and signal to background
ratios were determined using ActivityBase software (IDBS) and data
normalisation was done using Vortex software (dotmatics). Compounds
reaching at least 20% eﬀect relative to control treated animals (sine-
fungin/DMSO control treatment is 100% eﬀect, DMSO only control
treatment is 0% eﬀect) were selected for further analysis. Dose-response
assays were performed using concentrations between 0.08 μM and
80 μM sinefungin. GFP ﬂuorescence was measured using a PHERAstar
FS microplate reader after 4 h and analysed using IDBS ActivityBase
software.
2.8. Fluorescence microscopy
GFP intensity was measured as described (Philippe et al., 2017).
Brieﬂy, 10 animals were immobilized using 0.5% l-phenoxy-2-propanol
on slides with 1% agarose cushions and covered with a cover slip. GFP
and mCherry ﬂuorescence were captured using a Zeiss Axioplan 2
ﬂuorescence microscope and analysed using ImageJ software
(Schneider et al., 2012). The GFP ﬂuorescence intensity of each animal
was normalised with respect to its mCherry ﬂuorescence intensity.
Statistical analysis was done using Microsoft Excel 2013 or GraphPad
Prism version 5.00 for Windows, GraphPad Software, San Diego, CA,
USA.
2.9. Reverse transcription-quantitative PCR (RT-qPCR)
Total RNA was prepared as described (Philippe et al., 2017). Brieﬂy,
1ml of liquid culture containing 750 - 1000 adults were collected and
washed once in 1ml M9 buﬀer. Then total RNA was prepared using the
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PureLink RNA Mini kit (Life Technologies) with modiﬁcations for
TRIzol treated samples and DNase treatment as described by the man-
ufacturer. For cDNA synthesis, total RNA was reverse transcribed using
oligo(dT) primers and M-MLV Reverse Transcriptase, according to the
manufacturer's instructions (Promega). qPCR assays are described in
detail elsewhere (Philippe et al., 2017). Brieﬂy, qPCR assays were de-
signed using the Universal Probe Library Assay Design Centre (Roche)
and were done in three technical replicates on a Roche Lightcycler 480
using standard settings.
Primers TAAAATTATCATGTTTTCAGGAC and GTTGCATCACCTTC
ACCCTC were used to detect the outron of gfp transcripts, and primers
CCACATGGTCCTTCTTGAGTTT and ATAGTTCATCCATGCCATGTGTA
were used to detect the last gfp exon (internal gfp amplicon). Primers
TATATTTCTTGTGTTTTGTTCGGATT and ACGGCCTTCTTCTTCTTGGT
were used to detect the outron of rps-3 transcripts, and primers TCCT
TCCAAAGGAACCACAC and TGCTGGGACTTGAACATCCT were used to
detect the last exon of rps-3 transcripts (internal rps-3 amplicon).
Data was analysed using the comparative CT method (Schmittgen
and Livak, 2008). Outron levels were standardised with respect to the
levels of the internal RNA amplicon. Outron levels detected in
untreated animals were deﬁned as 1.
3. Results and discussion
3.1. Sinefungin inhibits spliced leader trans-splicing in nematodes
We have generated a gfp reporter gene assay that detects the in-
hibition of SL1 spliced leader trans-splicing in living C. elegans (Fig. 1).
The reporter gene is expressed under the control of the vit-2 promoter,
limiting its expression to the intestine of L4 and adult hermaphrodite
animals (Kimble and Sharrock, 1983; MacMorris et al., 1992). vit-2
promoter controlled expression of the gfp reporter gene allows the
identiﬁcation of factors that inhibit SL1 trans-splicing in fully developed
animals, without complications in assay interpretation caused by eﬀects
on early development, which is particularly sensitive to the loss of
spliced leader trans-splicing (Ferguson et al., 1996). Ultimately, we
expect active compounds to interfere with nematode development, but
this will need to be tested independently.
Normally, the gfp initiation codon located upstream of a splice ac-
ceptor site is removed by SL1 trans-splicing, resulting in a transcript
Fig. 2. Sinefungin inhibits SL trans-splicing. A. Exposure
to sinefungin activates gfp reporter gene expression. PE796
animals in S complete medium supplemented with OP50
bacteria were either left untreated, treated with DMSO (2%)
or with 20 μM, 100 μM or 400 μM sinefungin in 2% DMSO for
21 h. gfp expression was then analysed by ﬂuorescence mi-
croscopy. In the micrographs shown the exposure time was
5ms and the scale bar represents 100 μm. The graph plots gfp
expression standardised with respect to mCherry in arbitrary
units. 10 animals were analysed for each treatment, shown
are the median and ﬁrst and third quartile. (“ns” indicates
values not signiﬁcantly higher than in untreated and DMSO
treated animals (P > 0.05; ANOVA), ** indicates values
signiﬁcantly higher than in untreated and DMSO treated
animals (P ≤ 0.01; ANOVA)). B. Treatment with sinefungin
inhibits SL trans-splicing. PE796 animals were treated with
sinefungin for 21 h as described under (A) and then har-
vested for cDNA synthesis as described in Materials and
Methods. SL1 trans-splicing of gfp reporter transcripts and of
endogenous rps-3 transcripts was analysed by reverse tran-
scription followed by qPCR. The schematic diagrams indicate
the location of primers used for PCR on the gfp and rps-3
RNAs. “outron” indicates the primer pair used to measure the
eﬃciency of SL1 spliced leader trans-splicing, and “internal”
indicates the primer pair used to measure RNA levels. Outron
sequences are shown in blue and the SL1 acceptor sites in
pink. gfp and rps-3 open reading frames are shown in green
and brown, respectively. The levels of non-trans-spliced
outron-gfp reporter transcripts and of outron-rps-3 transcripts
were standardised with respect to RNA levels measured using
the internal primer pairs, and the levels in untreated animals
were deﬁned as 1. Note that an increase in outron-gfp RNA
levels reﬂects the inhibition of trans-splicing. The graphs
show the average of three biological replicates, error bars
indicate the standard deviation. Inhibition of SL1 trans-spli-
cing, as measured by outron retention, increases signiﬁcantly
between treatments with 20 μM, 100 μM and 400 μM sine-
fungin (P≤ 0.05; t-test). (For interpretation of the references
to colour in this ﬁgure legend, the reader is referred to the
Web version of this article.)
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with a truncated open reading frame unable to produce functional GFP
(Philippe et al., 2017) (Fig. 1B). The inhibition of SL1 trans-splicing
allows the production of functional GFP by translation of non-pro-
cessed, outron-containing mRNA. The gfp reporter gene used minimises
eﬀects caused by the inhibition of factors shared between SL1 trans-
splicing and intron removal by cis-splicing (Hannon et al., 1991;
Maroney et al., 1996). The gfp reporter gene contains three introns; any
compound inhibiting cis-splicing would interfere with the removal of
introns and thus generate transcripts with two premature termination
codons. Such transcripts are degraded by nonsense-mediated RNA
decay (Hug et al., 2016), and, if translated, would create a truncated
protein terminated 50 amino acids after the GFP chromophore. The
selectivity of the assay for inhibition of SL1 trans-splicing is supported
by the observation that treatment of PE796 animals carrying the gfp
reporter gene with 20 μM, 100 μM and 400 μM isoginkgetin, a known
inhibitor of cis-splicing (O'Brien et al., 2008), did not lead to reporter
gene activation (data not shown). However, we cannot rule out that our
assay would identify compounds inhibiting both SL1 trans-splicing and
cis-splicing. It will be necessary to conﬁrm speciﬁcity for SL1 trans-
splicing by ruling out inhibition of cis-splicing, preferably using a cell-
based assay derived from parasite hosts.
Sinefungin, a naturally occurring nucleoside isolated from
Streptomyces griseolus and S. incarnates with structural similarities with
S-adenosyl-1-methionine, has antitrypanosomal activity and inhibits SL
trans-splicing in these organisms (Bachrach et al., 1980; Dube et al.,
1983; McNally and Agabian, 1992). The precise mechanism of this in-
hibition is not known. Sinefungin acts as a competitive inhibitor of
methyltransferases involved in the methylation of nucleic acids and its
inhibition of spliced leader trans-splicing has been linked to an inhibi-
tion of the formation of the hypermethylated cap 4 structure of SL RNA
(Pugh et al., 1978; McNally and Agabian, 1992). However, sinefungin
also inhibits methyltransferases involved in the methylation of proteins,
a process required for the assembly of snRNPs (Meister et al., 2001;
Zheng et al., 2012). It is therefore possible that sinefungin acts at sev-
eral levels to inhibit SL trans-splicing in trypanosomes.
As C. elegans SL RNAs are also subject to hypermethylation of the
cap structure (Thomas et al., 1988) we examined whether sinefungin
could also inhibit SL trans-splicing in C. elegans, using the PE796 strain
carrying a gfp reporter gene engineered to produce GFP when SL trans-
splicing is inhibited (Fig. 2). We observed that exposure to sinefungin
caused increased expression of this gfp reporter gene. GFP expression
was weak but visible in PE796 animals treated with 20 μM sinefungin,
and was very clear in treatments with 100 μM and 400 μM sinefungin,
compatible with a dose-dependent inhibition of SL1 trans-splicing
(Fig. 2A).
Since sinefungin was dissolved in DMSO, to rule out that DMSO
treatment alone led to reporter gene activation, PE796 animals were
treated with 2% DMSO, the maximum DMSO concentration used
throughout this study. This did not result in reporter gene activation
(Fig. 2A) and, in agreement with observations by others (Katiki et al.,
2011), 2% DMSO did not have an obvious detrimental eﬀect on the
animals.
RT-qPCR was used to conﬁrm that gfp activation was indeed due to a
defect in SL trans-splicing. To detect the inhibition of trans-splicing we
measured the levels of outron-containing transcripts using primers
targeting the outron regions of gfp reporter gene transcripts and of rps-3
transcripts (Fig. 2B). rps-3 is an endogenous gene known to be subject to
SL1 trans-splicing (Morton and Blumenthal, 2011). The levels of outron-
containing transcripts were normalised to amplicons derived from the
coding regions of the gfp and rps-3 transcripts, respectively. The pro-
portion of non-trans-spliced, outron-containing gfp and rps-3 transcripts
increased upon exposure to sinefungin in a dose-dependent manner,
conﬁrming that sinefungin inhibits SL trans-splicing.
Exposure to sinefungin causes a delay of C. elegans development and
reduces fecundity. When growing C. elegans eggs or synchronised L1
larvae to adults on plates in the absence or presence of 1% DMSO, or of
400 μM sinefungin and 1% DMSO, we observed that exposure to sine-
fungin led to a 12 h −15 h delay in the appearance of adult animals.
Egg laying of animals exposed to sinefungin (400 μM sinefungin, 1%
DMSO) was signiﬁcantly reduced compared to control animals exposed
to 1% DMSO only; from an average of 64 eggs laid per animal (n=10)
during a 36 h period to 48 eggs laid per animal (n= 10) during a 48 h
period in the presence of sinefungin (t-test, p≤ 0.001). The proportion
of eggs hatched was similar for animals treated with sinefungin/DMSO
compared to DMSO only treated animals (89% and 87.5%, respec-
tively). Given that drug uptake of C. elegans grown on plates is highest
in the ﬁrst 24 h, and that the presence of live bacteria over time sig-
niﬁcantly reduces the drug concentration in the medium (Zheng et al.,
2013), the developmental delay and reduced fecundity observed are
most likely a reﬂection of a mild treatment with sinefungin.
To our knowledge this is the ﬁrst demonstration of a compound
inhibiting SL1 trans-splicing in nematodes. The inhibition of SL RNA
cap hypermethylation by sinefungin may be responsible for the in-
hibition of SL trans-splicing (McNally and Agabian, 1992). However, as
other key steps such as Sm protein assembly also require protein me-
thylation, sinefungin may have a broader eﬀect on SL trans-splicing
(Meister et al., 2001; Gonsalvez et al., 2007). Furthermore, sinefungin is
an inhibitor of a large number of S-adenosyl-1-methionine dependent
protein, RNA and DNA methyltransferases (Pugh et al., 1978; Barbes
et al., 1990; Zheng et al., 2012). Therefore we cannot exclude the
possibility that the inhibition of spliced leader trans-splicing, and the
detrimental eﬀects on development and egg laying caused by sine-
fungin, are due to an inhibition of methyltransferases acting in other
pathways. We can also not be sure that the inhibition of SL1 trans-
splicing is the direct cause of the developmental delay and reduced
fecundity, because of the eﬀects of sinefungin on a wide range of me-
thyltransferases.
Sinefungin is not a suitable anthelmintic agent because of its toxi-
city to hosts (Zweygarth et al., 1986). However, one possible route to a
new anthelmintic drug would be the identiﬁcation of sinefungin's key
target(s) in spliced leader trans-splicing, which in turn would allow the
development of less toxic, target-selective derivatives (Zweygarth et al.,
1986; Devkota et al., 2014). In the work described here we have used
sinefungin as an active compound for high-throughput screening assay
development.
3.2. Development of a high-throughput screening assay protocol to identify
inhibitors of SL1 trans-splicing
The HTS-ready assay was established at the facilities of the
European Screening Centre, Newhouse, Scotland. Eggs isolated from
gravid PE796 adults were synchronised at L1 stage in liquid culture,
and then grown to adult stage and used for assay development. Adult
PE796 animals were used because the vit-2 promoter in the reporter
construct is active in late L4/adult stage of transgenic animals (Kimble
and Sharrock, 1983; MacMorris et al., 1992; Philippe et al., 2017).
Animals were dispensed into black opaque 384-well plates with round
wells with a high base (Greiner Bio-One, 784076). These plates were
used to minimise interference from background ﬂuorescence or from
ﬂuorescence from other wells (Jones et al., 2012) and the conical
geometry facilitates reading of the wells from the top of the plate.
GFP ﬂuorescence resulting from the activation of the reporter gene
by inhibition of SL trans-splicing was measured using a PHERAstar FS
microplate reader. We ﬁrst compared the eﬀect of the culture volume
by manually dispensing animals in either 10 μl or 20 μl of medium
(Fig. 3A) followed by addition of sinefungin in DMSO or DMSO only
using an acoustic liquid dispenser (Echo 550, Labcyte, Inc.). As the live
animals are in constant motion in liquid media, we decided to compare
two signal reading modes of the PHERAstar FS microplate reader: re-
peat measurements at a single point at the centre of each well; or orbital
averaging where measurements are taken along a deﬁned orbit. The
signal-to-background (S/B) ratios (equations (2) and (3)) comparing gfp
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ﬂuorescence in sinefungin treated animals with control DMSO- treated
animals were between 2.94 and 3.77 (Fig. 3A), indicating largely si-
milar gfp reporter gene activation measured independent of read mode
and culture volume. Importantly, the S/B ratios also reﬂect the acti-
vation of gfp reporter gene expression observed by microscopy and RT-
qPCR in Fig. 2.
To assess the suitability of the assay for HTS, the Z′-factor was
calculated for each condition (Zhang et al., 1999). A Z′-factor value of
0.5 or above indicates clear distinction between positive signals and
background and is indicative of a robust HTS assay. Using 20 μl culture
volume consistently ensured a Z′-factor≥ 0.5 and a signal/background
window>3 while the Z′-factor for 10 μl volume was lower than 0.5
(Fig. 3A), indicating that the assay is more robust when animals are in
20 μl cultures, independent of whether signal was detected using single
or orbital average read mode. In subsequent experiments with 384-well
plates, animals were dispensed in 20 μl.
Fig. 3B shows a comparison of dispensing animals either manually
or mechanically, using either a Multidrop Combi Reagent dispenser or a
Matrix Wellmate. The S/B ratios> 2.46 indicate that GFP reporter gene
activation was observed in all sinefungin treated samples. Multidrop
Combi Reagent dispenser and Pherastar FS microplate reader in orbital
averaging read mode was the only combination that resulted in a Z′-
factor value≥ 0.5 (0.51), and was therefore used in subsequent ex-
periments.
To establish the ideal workﬂow for the HTS, we then investigated
the time-frame over which a robust signal can be observed. A previous
analysis using ﬂuorescence microscopy indicated that gfp reporter gene
expression was detectable after about 4 h of sinefungin treatment.
PE796 worms were exposed to sinefungin for a period of up to 18 h,
during which ﬂuorescence was measured at regular intervals (Fig. 4A).
At all time points the S/B ratio was similar and between 4.02 and 4.80.
The Z′-factor was around 0.9 at the early time points, and was reduced
at later times, although still clearly> 0.5, indicating that the assay is
robust over the 4–18 h time window.
To test the consistency of the assay we scaled up the number of wells
representing positive and negative controls, with 192 wells with sine-
fungin-treated animals and 192 wells DMSO control-treated animals
(Fig. 4B). The S/B ratios of 2.79 and 2.43 reﬂect the clear activation of
the reporter gene in response to the addition of sinefungin at both 4 h
and 19 h time points, and Z′-factors of≥ 0.55 conﬁrm the robustness of
the assay.
We also tested whether the assay can be adapted to the 1536-well
plate format. 5–10 animals in 10 μl medium were dispensed into each
well, and then 768 wells were treated with sinefungin/DMSO and 768
wells with DMSO only (Fig. 4B). The S/B ratios of 4.09 and 4.47 in-
dicated robust signal detection in wells treated with sinefungin, and Z′-
factors of≥ 0.50 indicate that the assay can also be executed using the
1536-well plate format.
These experiments also indicate that while prolonged incubations
are possible, this assay is more robust with shorter incubation times.
The increase in the error associated with replicates and the resulting
reduction in Z′-factor over longer incubation is very likely linked to
evaporation occurring in wells along edges of the plate, which was
observed by eye. To reduce the eﬀect of evaporation, assay plates were
Fig. 3. Culture volume, read mode, and dispen-
sing aﬀect high-throughput screen robustness. A.
Culture volume and read mode. 20–25 animals were
manually transferred into wells of a 384-well plate
in either 10 μl or 20 μl of S-complete medium con-
taining OP50 bacteria. Animals were then exposed
to 400 μM sinefungin/2% DMSO (32 wells) or with
2% DMSO only (32 wells), using an ECHO 550
acoustic liquid handler to dispense the compounds.
Fluorescence was measured after 21 h using either
single read or orbital averaging mode of a
PHERAstar FS microplate reader. The graphs show
ﬂuorescence measurements taken in either single
read or orbital averaging mode for 20 μl cultures for
the treatments with sinefungin/DMSO or with
DMSO only. The table shows signal/background ra-
tios (S/B) with standard deviations and Z′-factors
from the analysis using orbital averaging mode and
single read mode for both culture volumes, calcu-
lated as described in Materials and Methods. B.
Dispensing method and read mode. 20–25 animals
were transferred into wells of a 384-well plate in
20 μl of S-complete medium containing OP50 bac-
teria using the methods indicated. Animals were
then treated with 400 μM sinefungin/2% DMSO (32
wells) or with 2% DMSO only (32 wells).
Fluorescence was measured after 21 h using a
PHERAstar FS microplate reader using either single
read or orbital averaging mode. The graph shows
ﬂuorescence measurements of the treatments with
sinefungin/DMSO or with DMSO only taken in the
orbital averaging mode. The table shows signal/
background ratios (S/B) with standard deviations
and Z′-factors for measurements taken in single read
and orbital averaging mode.
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incubated in sealed containers humidiﬁed by inclusion of distilled
water-soaked tissues.
We performed a pilot screen of 6775 small molecules from the
BioAscent Compound Cloud of diverse lead like structures, from the
NIH Clinical Collection and cherry picked from the SelleckChem li-
braries collection. Because of the library formulation, in combination
with the detrimental eﬀect on C. elegans of DMSO concentration in
excess of 2% (Katiki et al., 2011), the highest compound concentration
we could perform the screen at was 50 μM. We conﬁrmed that exposing
PE796 to 40 μM sinefungin does result in reporter gene activation and
the inhibition of gfp and rps-3 SL1 trans-splicing (data not shown). The
screen was done in 384-well plates with PE796 animals, and OP50
bacteria were included as food source. Each plate also included PE796
animals treated with sinefungin/DMSO and DMSO only. The results
from one 384-well plate, testing components of the BioAscent
Compound Cloud, are shown as example in Fig. 4C. 68 compounds had
a ≥ 20% eﬀect relative to sinefungin/DMSO control treated animals,
and were further investigated. Three of these, BCC0054675,
BCC0052390 and BCC0115265 are shown in Fig. 4C. Of these 68, 29
were eliminated because of their known ﬂuorescent properties. 39
compounds were further analysed by dose-response assays, including
the three compounds from Fig. 4C. 23 of these compounds, including
BCC0052390 and BCC0054675, did not produce a dose-dependent in-
crease in ﬂuorescence and were therefore not further analysed. Visual
inspection showed that 11 of the 16 remaining compounds were
ﬂuorescent and were therefore not further pursued. Five compounds
(Cloroxine, Risperidone, Nitazoxanide, BCC0100201 and BCC0115265)
were re-tested by high resolution ﬂuorescence microscopy. Treatment
with up to 160 μM compound did not produce the typical intestinal gfp
ﬂuorescence produced for example by sinefungin (Fig. 2), ruling these
Fig. 4. Treatment with sinefungin produces a
robust signal that can be detected for at least
19 h and scaled up for high-throughput
screening. A. Time course. PE796 animals were
grown, dispensed and treated with 800 μM sine-
fungin/2% DMSO (24 wells) or 2%DMSO (24 wells)
as described. The graph shows ﬂuorescence mea-
surements at the indicated times after compound
addition for the treatment with sinefungin/DMSO
and for DMSO only. B. Assays in 384- and 1536-well
plates. Animals in 192 or 796 wells were either
treated with 800 μM sinefungin/2% DMSO or with
DMSO only and GFP ﬂuorescence was measured
after 4 h and 19 h of incubation. The graphs show
the measurements taken after 4 h and 19 h. Signal to
background (S/B) ratios with standard deviations
and Z′-factors were calculated as described. C. Pilot
screen of drug-like compounds. PE796 animals were
dispensed into 384-well plates in the presence of
OP50 bacteria. On each plate, 32 wells were treated
with 2% DMSO/800 μM sinefungin, and 32 wells
with 2% DMSO. Animals in the remaining wells
were treated with 50 μM compound/2% DMSO, and
ﬂuorescence was analysed after 4 h exposure. The
graph shows ﬂuorescence caused by control treat-
ments with sinefungin/DMSO and with DMSO only,
and with compounds from the BioAscent Compound
Cloud from a typical 384-well plate. BCC0052390,
BCC0054675 and BCC0115265 were further in-
vestigated.
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compounds out as inhibitors of SL1 trans-splicing. This screen was re-
peated in the absence of OP50 bacteria, and similarly failed to identify
any hit compounds. The screening of this limited number of compounds
did not lead to the identiﬁcation of any hits. However, the ease with
which we were able to rule out compounds as bona ﬁde inhibitors of SL1
trans-splicing supports the suitability of our gfp-reporter assay for the
detection of inhibitors of SL1 trans-splicing.
3.3. Modiﬁcation of C. elegans culture conditions
The experiments described in Figs. 3 and 4 were performed with
incubations that contained OP50 E. coli. To determine whether the in-
clusion of the bacteria, which could interfere with the assay by for
example metabolising compounds (Luo et al., 2009), is necessary, we
compared the assay performance in the presence and absence of bac-
teria (Fig. 5). PE796 animals were treated with 400 μM and 800 μM of
sinefungin and DMSO, or with DMSO only, and GFP expression was
measured after 4 h, 6.5 h and 21.5 h. S/B ratios were similar for treat-
ments with/without OP50 bacteria, and although Z′-factor values were
generally lower in treatments without OP50, they were ≥ 0.50, in-
dicating that the omission of bacteria does not aﬀect the HTS quality of
the assay.
3.4. Genetic modiﬁcation of C. elegans increases robustness of the high-
throughput screening assay
The cuticle of C. elegans, which is one of the entry points for drugs, is
an extracellular matrix that lines the exterior, oral and rectal cavities,
and acts as an exoskeleton. The major component is collagen, and other
components are cuticulin, lipids and glycoproteins. The cuticle is rela-
tively impermeable to chemical compounds (Cox et al., 1981; Page and
Johnstone, 2007), thus treatments or mutants that increase the per-
meability of the cuticle could increase the entry of drugs and reduce the
eﬀective concentration required, increasing the sensitivity during the
screening process.
The bus-8 gene is required for epidermal integrity and cuticle sur-
face formation (Partridge et al., 2008). Several mutant alleles of this
gene have been isolated that aﬀect the structure of the cuticle, in-
cluding the e2698 allele (Gravato-Nobre et al., 2005). bus-8 (e2698)
mutants are phenotypically normal in terms of appearance and move-
ment but have a high permeability for various small molecules
(Partridge et al., 2008). Also, bus-8 (e2698) mutants have been pre-
viously used in the screening of drug libraries (McCormick et al., 2013).
We produced PE797, a cuticle defective transgenic C. elegans strain
with the bus-8 (e2698) allele and the spliced leader trans-splicing GFP
reporter construct. PE797 and PE796 animals were exposed to 400 μM
and 800 μM sinefungin/DMSO or to DMSO only, and GFP ﬂuorescence
was measured after 4 h, 6.5 h and 21.5 h (Fig. 6). Treatment of PE797
animals with sinefungin produced a stronger signal with statistically
signiﬁcantly higher S/B ratio compared to PE796 animals at all time
points and sinefungin concentrations (One-way ANOVA, p < 0.01).
This was also reﬂected in the higher Z′-factor values obtained with
PE797 animals. This is compatible with the cuticle being a signiﬁcant
obstacle to small compounds, and identiﬁes a strategy to enhance the
sensitivity of the assay, by increasing cuticle permeability.
In conclusion, we have shown that treatment of C. elegans with si-
nefungin aﬀects development and reduces fecundity. We have also
shown that sinefungin acts as an inhibitor of SL1 trans-splicing in C.
elegans, however it is not clear whether these two eﬀects of sinefungin
treatment are linked. Using sinefungin, we have developed a robust,
GFP-based high-throughput screening assay protocol that is selective
for the identiﬁcation of compounds that inhibit SL trans-splicing. A pilot
screen of 6775 compounds has identiﬁed a small number of candidate
positives which were identiﬁed as false positives in repeat tests. This
gives conﬁdence that the number of false positives during screening of
other compound libraries will be manageable. We have further identi-
ﬁed modiﬁcations of the assay, by changing culture conditions and
using C. elegans strains with a more permeable cuticle, that enhance the
versatility and sensitivity of this screen.
Here we have used a microplate reader to detect GFP ﬂuorescence.
The assay is also suitable for analysis by high content imaging. This
would allow us to eliminate autoﬂuorescent compounds at an early
stage and has the added advantage to allow direct visualisation of any
eﬀects on C. elegans morphology and behaviour.
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